Whilst osimertinib and targeted therapy for mutations such as anaplastic lymphoma kinase (ALK) and ROS1 have demonstrated some clinical benefit in patients lacking these EGFR mutations,16, 17 they do not fully address the broader NSCLC population without these mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.